Issue link: https://www.e-digitaleditions.com/i/1543258
36 February 2026 Inhalation High-purity medical propellants Orbia's Pharma Business Unit is part of its Fluor & Energy Materials group; one of Orbia's five core busi- nesses. e Pharma BU specializes in the develop- ment, manufacture and supply of high-purity medical propellants under the Zephex ® brand, which are used globally, in a large proportion of metered dose inhal- ers (MDIs) for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Orbia is expanding capacity for its next-generation, low-global-warming-potential propellant Zephex 152a, supporting pharmaceutical customers in tran- sitioning to more sustainable medical propellants, while maintaining the supply of Zephex 134a, the most widely-used propellant in the world. Its exper- tise in fluorine chemistry, stringent quality standards and global manufacturing footprint enable this unit to serve pharmaceutical markets worldwide. Orbia United Kingdom www.orbia.com Fast to clinic formulation platform for DPI products Intertek's new partnership with CrystecPharma sup- ports global clients in accelerating development time- lines for inhaled medicines, particularly dry powder inhalers (DPIs). A "fast to clinic" platform can enable rapid product development from the initial formu- lation concept to GMP clinical manufacturing in less than half the time typically required. is highly agile capability can allow clients aiming to formulate new small or large (biologic) molecules, or repurpose existing active pharmaceutical ingredients, to benefit from technology that enables new forms of molecules and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com DPI and nasal delivery formulation, device and manufacturing Hovione provides specialist expertise and leadership in particle engineering and formulation development to ensure that your inhalation and nasal therapies are engineered for success from start to finish. Fully inte- grated in one site, Hovione offers simple, patented and globally competitive dry powder inhalers— disposable, capsule, blister, large dose and high performance DPIs—which are available for fully integrated, turnkey development with formulation and for licensing. Expanding our inhalation offering, Hovione provides advanced nasal powder delivery devices, designed for local, systemic and nose-to- brain applications. Hovione—Delivering solutions, every breath of the way. Hovione Portugal: +351 21 982 9000 hovione.com/contact-us www.hovione.com Role of excipients for respiratory delivery Building upon more than 20 years of experience, Lonza continues to drive research in formulation for inhaled delivery of biologics. Excipient choice in drug formulation plays a key role in this process, and when combining a large molecule with one or more excip- ients, factors such as their own properties, route of administration, dosage form and processing condi- tions need to be considered. With dedicated technol- ogies and facilities, Lonza's scientists are identifying new, leading approaches with excipients and provid- ing support for navigating the regulatory landscape. Lonza Small Molecules US: +1 813 286-0404 small.molecules@lonza.com www.lonza.com